What were Schering-Plough's main revenue drivers in 2000?

Schering-Plough's primary revenue driver in 2000 was its pharmaceutical segment, which generated $8.3 billion in sales. Key products contributing significantly to this were the CLARITIN family of products (including CLARITIN and CLARITIN-D) and the INTRON A/REBETRON Combination Therapy (containing REBETOL and INTRON A), alongside PEG-INTRON.

What are the primary risks and uncertainties facing Schering-Plough, as disclosed in this filing?

The primary risks and uncertainties include significant ongoing litigation, particularly patent disputes related to CLARITIN and generic challenges, as well as government investigations into pricing and marketing practices. Additionally, manufacturing compliance issues with FDA Good Manufacturing Practices (GMPs) have led to production problems and negatively impacted the 2001 sales and earnings outlook. The upcoming expiration of key patents, such as for CLARITIN, also presents a material risk.

How is the company addressing the FDA's findings regarding manufacturing facilities?

The company has taken extensive measures to enhance its manufacturing processes and controls in response to FDA inspection reports citing GMP deficiencies. However, the FDA has advised that these deficiencies must be resolved before approving pending New Drug Applications, such as for CLARINEX (desloratadine) Tablets. The company is actively working to resolve these issues, but their resolution and impact on future sales remain subject to substantial risks and uncertainties.

What is the potential impact of patent expirations on Schering-Plough's business?

The expiration of patents for key products, particularly the loratadine compound patent for CLARITIN in the U.S. in 2002 and the desloratadine patent in 2004, poses a significant risk. This is exacerbated by ongoing litigation with generic manufacturers challenging the validity of these patents. A loss of patent protection could lead to increased generic competition and a substantial reduction in sales for these important products.

MRK 10-K FY2000 Annual Report — Revenue, Net Income, EPS

Summary

Schering-Plough Corporation's 2000 Form 10-K highlights a year of solid revenue growth, driven primarily by its pharmaceutical segment, which saw an 8% increase to $8.3 billion. Key products like CLARITIN and INTRON A/REBETRON Combination Therapy showed strong performance, though some older products in the allergy/respiratory and cardiovascular segments experienced declines. The company continued to invest heavily in research and development, representing approximately 14% of net sales in 2000, focusing on critical therapeutic areas like oncology, infectious diseases, and cardiovascular conditions. However, the report also flags significant challenges, particularly concerning manufacturing compliance with Good Manufacturing Practices (GMPs) at facilities in New Jersey and Puerto Rico. The FDA has cited deficiencies, which have led to reduced sales of certain products and a downward revision of 2001 sales and earnings forecasts. Furthermore, the company faces numerous legal proceedings, including patent litigation related to CLARITIN generics and investigations into marketing practices and pricing, which could materially impact future financial results.

Key Highlights

1Consolidated net sales increased by 8% to $9.8 billion in 2000, with the pharmaceutical segment contributing $8.3 billion.
2The CLARITIN family of products and INTRON A/REBETRON Combination Therapy demonstrated strong sales growth, indicating their importance to the company's revenue.
3Research and development expenditures were substantial, reaching $1.33 billion in 2000, representing approximately 14% of net sales, underscoring a commitment to innovation.
4Significant FDA inspections identified GMP deficiencies at manufacturing facilities, leading to production issues and a negative outlook for 2001 sales and earnings.
5The company is involved in extensive litigation, including patent disputes over CLARITIN and investigations related to pricing and marketing practices, posing potential financial and operational risks.
6Patent expirations for key products, such as CLARITIN in 2002 and desloratadine in 2004, are a material concern, especially given ongoing litigation regarding their validity.
7Despite overall sales growth, certain product lines, including PROVENTIL, VANCENASE, VANCERIL, and IMDUR, experienced sales declines in 2000.

Merck & Co., Inc. Annual Report, Year Ended Dec 31, 2000

Summary

Key Highlights

Frequently Asked Questions